In Utero Exposure to Acetazolamide and Pregnancy Outcomes: A Cohort Study
Drug Safety · 18.11.2026
DOI: 10.1007/s40264-026-01718-x ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Drug Safety, online erschienen am 18.11.2026. Verfasst von Camille Reinaud und 7 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Par…. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Background and Objective Data on pregnancy outcomes following acetazolamide exposure remain limited. The main safety issues relate to suspected teratogenic effects, supported by similarities between malformations reported in humans and animals. Other concerns include intrauterine growth restriction, amniotic fluid anomalies, and neonatal electrolyte imbalances. This study aimed to describe pregnancy outcomes and neonatal characteristics following acetazolamide exposure during pregnancy and to assess the association between first-trimester exposure and adverse pregnancy outcomes.
Methods
We conducted a retrospective observational cohort study using data from the French national Teratology Information Service (Centre de Référence sur les Agents Tératogènes, CRAT). We included all prospective pregnancies exposed to acetazolamide with a known outcome and an estimated delivery date before 1 January, 2024. The study proceeded in two stages. First, we described pregnancy and neonatal outcomes among all acetazolamide-exposed pregnancies, overall and according to timing of exposure (descriptive analysis). Second, we assessed the association between first-trimester acetazolamide exposure and adverse pregnancy outcomes, using a composite outcome including spontaneous miscarriage, medical termination of pregnancy, stillbirth, and major congenital malformation. We conducted this comparative analysis using a matched unexposed control group (1:4 ratio) randomly selected from the same database after exclusion of known teratogenic exposures and genetic disorders. Conditional logistic regression was used to estimate crude conditional odds ratios.
Results
Between 1988 and 2024, 135 prospective pregnancies were referred to the CRAT: 114 (84.4%) resulted in live births, 8 (5.9%) in miscarriages, 9 (6.7%) in elective terminations, 3 (2.2%) in medical abortions, and 1 (0.7%) in stillbirth. Among 87 first-trimester exposures with documented malformation status, three major congenital malformations unrelated to genetic disorders were identified (3.4%, 95% confidence interval 0.72–9.75). In the comparative analysis, first-trimester acetazolamide exposure was not associated with an adverse pregnancy outcome (crude conditional odds ratio = 1.03, 95% CI 0.51–2.09). Major congenital malformation rates did not differ between exposed (2.6%, 2/78) and unexposed pregnancies (2.8%, 9/327) [crude conditional odds ratio = 1.03, 95% confidence interval 0.21–4.99).
Conclusions
This study reports the largest cohort of acetazolamide-exposed prospective pregnancies to date and does not identify evidence supporting previous concerns regarding an association with major congenital malformation. However, given the limited sample size, small increases in risk cannot be excluded, and acetazolamide should be used during pregnancy only when no effective alternative exists.
Autor:innen und Institutionen
- AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Paris, France.
- Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Institute of Clinical Pharmacology and Toxicology, Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germ…
- Limbach Genetics MVZ Humangenetik Bremen, Bremen, Germany.
- Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d'Ophtalmologie, 75013 Paris, France.
- AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Paris, France. benoit.marin@aphp.fr.
- Sorbonne Université, INSERM, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Pari…
Zitieren
APA
Reinaud, C., Hoeltzenbein, M., Touitou, V., Vauzelle, C., Elefant, E., Beghin, D., Marin, B., & Coulm, B. (2026). In Utero Exposure to Acetazolamide and Pregnancy Outcomes: A Cohort Study. Drug Safety. https://doi.org/10.1007/s40264-026-01718-x
Vancouver
Reinaud C, Hoeltzenbein M, Touitou V, Vauzelle C, Elefant E, Beghin D, et al. In Utero Exposure to Acetazolamide and Pregnancy Outcomes: A Cohort Study. Drug Safety. 2026. doi:10.1007/s40264-026-01718-x
BibTeX
@article{Reinaud2026,
author = {Reinaud, Camille and Hoeltzenbein, Maria and Touitou, Valérie and Vauzelle, Catherine and Elefant, Elisabeth and Beghin, Delphine and Marin, Benoît and Coulm, Bénédicte},
title = {In Utero Exposure to Acetazolamide and Pregnancy Outcomes: A Cohort Study},
journal = {Drug Safety},
year = {2026},
doi = {10.1007/s40264-026-01718-x}
}
EUVIMED